Welcome to the Population Approach Group in Europe

PK-PD model of morphine, pregabalin and their combination to assess the opioid-sparing effect	Monir Bertayli (1,2), Wouter Bakker (2), Geert Jan Groeneveld (2,3), Jeroen Elassaiss-Schaap (1) 2024 - Rome, Italy
An asymptotic description of a basic FcRn-regulated clearance mechanism and its implications for PBPK modelling of large antibodies	Csaba Katai (1), Shepard J. Smithline (2), Jeroen Elassaiss-Schaap (1), Craig J. Thalhauser (2), Sieto Bosgra (3) 2024 - Rome, Italy
Construction of IMPRES-M, a non-parametric impulse-response modeling method, in the context of varying pharmacokinetic profiles	Jeroen Elassaiss-Schaap, Lorenzo Cifelli and Paul H.C. Eilers 2024 - Rome, Italy
ODE-free survival modeling with full pharmacokinetic profiles in the IMPRES-M framework	Lorenzo Cifelli, Csaba Katai, Jeroen Elassaiss-Schaap 2024 - Rome, Italy
Structural model development with compartmental pharmacokinetic models for a range of small molecule subcutaneous data	Asina Gijasi (1,2), Jeroen Elassaiss-Schaap (1) 2024 - Rome, Italy
Evaluation of extrapolation potential of IMPRES-M, a non-parametric Impulse-Response Modeling framework when applied to pharmacokinetic profiles of different dosing frequencies	Zeyar Mohammed Ali, Lorenzo Cifelli, Jeroen Elassaiss-Schaap 2024 - Rome, Italy
An asymptotic description of a basic FcRn-regulated clearance mechanism and its implications for PBPK modelling of large antibodies	Csaba Katai (1), Jeroen Elassaiss-Schaap (1), Shepard J. Smithline (2), Craig J. Thalhauser (2), Sieto Bosgra (2) 2023 - A Coru�a, Spain
Implementation of Estimation Step Refinements to Support Runtime Reduction for Model Building in NONMEM� 7	Nivea M.F. Voelkner (1), Sonya C. Chapman (2), Aurelie Lombard (2), Jeroen Elassaiss-Schaap (1) 2022 - Ljubljana, Slovenia
Integration of the LeiCNS-PK3.0 PBPK framework and multiscale data to select anti-COVID19 drugs with favorable brain pharmacokinetics	Mohammed A. A. Saleh (1), Makoto Hirasawa (1), Ming Sun (1), Berfin G�lave (1), Jeroen Elassaiss-Schaap (1,2), Elizabeth C. M. de Lange (1) 2022 - Ljubljana, Slovenia
Mixing of variability in the log-domain with normal-domain variability components may lead to biased estimation	Jeroen Elassaiss-Schaap (1,2), Lisa Martial (1) 2022 - Ljubljana, Slovenia
Dose determination of morphine to investigate the analgesic effects of morphine and pregabalin in healthy subjects using a combined NONMEM model	Monir Bertayli (1), Jeroen Elassaiss-Schaap (1) 2022 - Ljubljana, Slovenia
Predicting the impact of healthy aging on the brain pharmacokinetic profiles using a translational modeling approach	Mohammed A. A. Saleh (1), Jeroen Elassaiss-Schaap (1,2), Elizabeth C. M. de Lange (1) 2021 - Online, In the cloud
Population PK Modelling of Treosulfan in Paediatric Allogeneic Transplant Patients	Theo Reijmers (1), Claudia Hemmelmann (2), Karl-Walter Sykora (3), Ajay Vora (4), Jochen Kehne (2), Ann-Kristin M�ller (2), Joachim Baumgart (2), Jeroen Elassaiss-Schaap (1,5) 2018 - Montreux, Switzerland
Population PK Modeling of Dapivirine released from Vaginal Rings	Theo Reijmers (1), Stefan Zeiser (1), Marieke van den Dobbelsteen (1), Annalene Nel (2), Jeremy Nuttall (2), Neli�tte van Niekerk (2), Jeroen Elassaiss-Schaap (1,3) 2017 - Budapest, Hungary
The proof is in the pee: Population asparagus urinary odor kinetics.	J. G. Coen van Hasselt(1), Jeroen Elassaiss-Schaap(1,2), Anuradha Ramamoorthy(3), Brian M. Sadler(4), Sreeneeranj Kasichayanula(5), Yin Edwards(6), Piet H. van der Graaf(1,7), Lei Zhang(1), John A. Wagner(8) 2016 - Lisboa, Portugal
Finding underlying longitudinal patterns in pharmaco-metabolomics data	W. van den Brink, R. Hartman, M. de Bruin, B. Gonzalez, J. Elassaiss-Schaap, P.H. van der Graaf, T. Hankemeier, E.C.M. de Lange 2016 - Lisboa, Portugal
Model-based analysis of the relationship between pembrolizumab exposure and efficacy in patients with melanoma and NSCLC: across indication comparison	M. Chatterjee, D.C. Turner, M. Ahamadi, Dinesh de Alwis, J. Elassaiss-Schaap*, T. Freshwater, R de Greef**, C. Li, K. Mayawala, J. Stone, A. Kondic* (presenting author) 2015 - Hersonissos, Crete, Greece
Modeling of tumor size reduction patterns in advanced melanoma under treatment with MK-3475, a potent antibody against PD-1	Jeroen Elassaiss-Schaap (1), Andreas Lindauer (1), Alexandre Sostelly (1)#, Malidi Ahamadi (2), Kevin Gergich (3), Peter Kang (3), Dinesh de Alwis (3) and Rik de Greef (1) 2014 - Alicante, Spain
Translational Pharmacokinetic/Pharmacodynamic Model of Tumor Growth Inhibition by the New Anti-PD1 Monoclonal Antibody MK-3475	Lindauer, A (1), Valiathan, C (2), Mehta, K (2), Philips, J (3), DeAlwis, D (1), de Greef, R (1), Elassaiss-Schaap, J (1) 2014 - Alicante, Spain
Population Pharmacokinetics of MK-3475, a human Anti-PD-1 Monoclonal Antibody in patients with progressive locally advanced or metastatic carcinoma, melanoma, and non-small cell lung carcinoma	Malidi Ahamadi (1), Marita Prohn (2), Stefaan Rossenu (2), Jung Hoon Lee (1), Rik de Greef (2), Dinesh de Alwis (1), and Jeroen Elassaiss-Schaap (2) 2014 - Alicante, Spain
Comparison of NONMEM Estimation Methods in the Application of a Markov-Model for Analyzing Sleep Data	Lindauer, A (1); Guo, Z (2); Zajic, S (3); Huang, S (2); Mehta, K (4); Kumar, B (3); Elassaiss - Schaap, J (1); Bauer, R (5); Clements, JD (3) 2013 - Glasgow, Scotland
Pharmacokinetic-Pharmacodynamic Modelling & Simulation of Org 52186, a V3 antagonist, in Support of a Challenge Agent Trial Design with dDAVP	Jeroen Elassaiss-Schaap (1), Bill Knebel (2), Ellen Hulskotte (1) and Rik de Greef (1) 2012 - Venice, Italy
Strategic comparator modeling and simulation to optimize dose selection for a dose-range finding study	D. A. Tatosian (1), J. Z. Peng (2), A. Zandvliet (1), J. Elassaiss � Schaap (1), Ashley Martucci (1), Rajesh Krishna (3), Anya Kauh (4), Gendrano III (5), B. Musser (4) 2012 - Venice, Italy
Allometric scaling in oncology disease progression from xenograft tumor growth to human non-small-cell lung cancer	Jeroen Elassaiss-Schaap 2010 - Berlin, Germany
Variability as constant coefficient of variation: Can we right two decades in error?	Jeroen Elassaiss-Schaap and Siem Heisterkamp 2009 - St. Petersburg, Russia
A population analysis on the effects of the CYP2D6 deficiency on pharmacokinetics and exposure of esmirtazapine in healthy volunteers.	O. Lillin-de Vries, T. Kerbusch, P-J. de Kam, N. Ivgy-May, R. Bursi 2008 - Marseille, France
Interspecies Population Modeling Of Pharmacokinetic Data Available At The End Of Drug Discovery	Jeroen Schaap 2007 - K�benhavn, Denmark
Mechanism-based model of the effect of co-administration of exogenous testosterone and progestogens on the hypothalamic-pituitary-gonodal axis in men	Strougo, A(1), Elassaiss-Schaap, J(2), de Greef, HJMM(2), Drenth, H(1) 2007 - K�benhavn, Denmark
Automation of Structural Pharmacokinetic Model Search in NONMEM: Evaluation with Preclinical Datasets	Jeroen Schaap (1), Stefan Verhoeven (2), Gerard Vogel (3), Martijn Rooseboom (3,4) and Rene van Schaik (2) 2007 - K�benhavn, Denmark